Joaquin C Brieva

Grants

Grants per year 2013 2013 2015 2019 2023 2024

• 4 Finished

Grants per year

Search results

• Finished

  Prot #M23‐696: A Phase 3b/4 Randomized, Open‐label, Efficacy Assessor Blinded Study, Comparing the Safety and Assessor Blinded Efficacy of Upadacitinib to Dupilumab in Subjects with Moderate to Severe Atopic Dermatitis (Level‐Up)

  Brieva, J. C. (PD/PI)

  AbbVie Inc.

  8/25/23 → 8/25/24

  Project: Research project

• Prot #LP0162-1337: Long-term extension trial in subjects with atopic dermatitis who participated in previous tralokinumab trials – ECZTEND

  Liszewski, W. J. (PD/PI) & Brieva, J. C. (Other)

  LEO Pharma Inc

  3/1/19 → 8/31/24

  Project: Research project

• Prot #WA29330: A Randomized, Double-Blind, Double-Dummy, Active-Comparator,Multicenter Study to Evaluate the Efficacy and Safety of Rituximab Versus MMF in Patients with Pemphigus Vulgaris

  Brieva, J. C. (PD/PI)

  Covance Inc., Genentech, Inc

  3/19/15 → 8/31/19

  Project: Research project

• Prot #JB121410: Videocapillaroscopy Assessment During Systemic Agent Therapy in Patients with Psoriasis

  Brieva, J. C. (PD/PI), Gordon, K. B. (Co-Investigator) & West, D. P. (Co-Investigator)

  AbbVie Inc.

  11/20/13 → 11/20/21

  Project: Research project